KLK3 and prostate cancer: Nevertheless, it may be feasible to use the METCAM/MUC18 to at least complement the current biomarker PSA and furthermore, to combine it with other prostate cancer biomarkers for accurately predicting the malignant potential of prostate cancer [4,5,6,7,8,18].